AlzeCure Pharma - ACD856: Phase I progressing after SAD data
AlzeCure has provided an update on the Phase I trial for ACD856, reporting that some promising data were observed during the initial single ascending dose (SAD) part of the study. Importantly, good tolerability was observed, with the drug’s pharmacokinetic profile tracking well from preclinical and Phase 0 (micro-dosing) data. Based on these, the SAD part of the study will be expanded to investigate some higher doses as the drug’s therapeutic window might be larger than initially expected. The subsequent multiple ascending dose (MAD) part remains on track to start in H221. We continue to forecast $4.6bn peak sales at 5% probability for ACD856’s potential use in Alzheimer’s disease (AD), which contributes SEK13.1/share (c 60%) to our valuation of SEK21.9/share We anticipate more details to be communicated at an R&D event on 1 September (09:00 CEST), which will cover ACD856 and the NeuroRestore platform in more detail.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.